Medtech and pharma companies have long viewed revenue growth as their highest priority. To increase the top line, many launched new products without addressing implications for legacy products, entered new therapeutic categories without a path to leadership, and expanded to all corners of the world without sufficient local scale.
Over time, unchecked growth created two problems. Leadership teams lost sight of the businesses that generated real value; and complexity...